Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.45 |
| ▸ | PI4KA | P42356 | 1/20 | 0.41 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.41 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.41 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | NT5E | P21589 | 1/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1491093 | 0.90 | POLB (0.54) | POLBNR3C2MAPK14KEAP1CYP17A1 | |
| SCHEMBL15428758 | 0.83 | POLB (0.57) | POLBNR3C2MAPK14KEAP1NPC1 | |
| SCHEMBL544287 | 0.79 | POLB (0.61) | POLBNR3C2MGLLIDO1NPC1 | |
| SCHEMBL544859 | 0.79 | POLB (0.61) | POLBMGLLNPC1MAPTRAB9A | |
| SCHEMBL14696791 | 0.79 | NR3C2 (0.46) | POLBNR3C2MAPK14KEAP1FAAH | |
| SCHEMBL15428751 | 0.79 | POLB (0.61) | POLBNR3C2MAPK14NPC1MAPT | |
| SCHEMBL544860 | 0.79 | POLB (0.61) | POLBNT5ENPC1RAB9AKMT2A | |
| SCHEMBL15779120 | 0.79 | KEAP1 (0.45) | POLBNR3C2MAPK14KEAP1FAAH | |
| SCHEMBL12299071 | 0.78 | POLB (0.56) | POLBNR3C2CYP1A2NPC1MAPK1 | |
| SCHEMBL403594 | 0.78 | POLB (0.56) | POLBCYP1A2NPC1MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8980837-B2 | Inhibitors of IAP | GENENTECH, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980837-B2 | Inhibitors of IAP | GENENTECH, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980837-B2 | Inhibitors of IAP | GENENTECH, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| EP-1778718-B1 | INHIBITORS OF IAP | GENENTECH INC (US) | 2014-10-08 | — | — | EP | disclosed |
| EP-1778718-B1 | INHIBITORS OF IAP | GENENTECH INC (US) | 2014-10-08 | — | — | EP | disclosed |
| WO-2012149157-A2 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-11-01 | — | — | WO | disclosed |
| US-20120202750-A1 | INHIBITORS OF IAP | GENENTECH, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202750-A1 | INHIBITORS OF IAP | GENENTECH, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202750-A1 | INHIBITORS OF IAP | GENENTECH, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-8110568-B2 | Inhibitors of IAP | GENENTECH, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-20070299052-A1 | Inhibitors of IAP | GENENTECH, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070299052-A1 | Inhibitors of IAP | GENENTECH, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070299052-A1 | Inhibitors of IAP | GENENTECH, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| CN-101035802-A | Inhibitors of IAP | GENENTECH INC (US) | 2007-09-12 | — | — | CN | disclosed |
| US-7244851-B2 | 1-[2-Cyclohexyl-2-(2-methylamino-propionylamino)-acetyl]-pyrrolidine-2-carboxylic acid (2-phenyl-2H-pyrazol-3-yl)-amide; inhibitors of IAP, for treating malignancies | GENENTECH, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244851-B2 | 1-[2-Cyclohexyl-2-(2-methylamino-propionylamino)-acetyl]-pyrrolidine-2-carboxylic acid (2-phenyl-2H-pyrazol-3-yl)-amide; inhibitors of IAP, for treating malignancies | GENENTECH, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244851-B2 | 1-[2-Cyclohexyl-2-(2-methylamino-propionylamino)-acetyl]-pyrrolidine-2-carboxylic acid (2-phenyl-2H-pyrazol-3-yl)-amide; inhibitors of IAP, for treating malignancies | GENENTECH, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| EP-1778718-A1 | INHIBITORS OF IAP | Genentech, Inc. (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006014361-A1 | INHIBITORS OF IAP | GENENTECH, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20060014700-A1 | 1-[2-Cyclohexyl-2-(2-methylamino-propionylamino)-acetyl]-pyrrolidine-2-carboxylic acid (2-phenyl-2H-pyrazol-3-yl)-amide; inhibitors of IAP, for treating malignancies | GENENTECH, INC. (US) | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299052-A1 | Inhibitors of IAP | XIAP, BIRC5, BIRC3 | POLB 4407/4885NR3C2 4838/4885MAPK14 3933/4885 |
| US-20120202750-A1 | INHIBITORS OF IAP | XIAP, BIRC5, BIRC3 | POLB 4407/4885NR3C2 4838/4885MAPK14 3933/4885 |
| US-20060014700-A1 | 1-[2-Cyclohexyl-2-(2-methylamino-propionylamino)-acetyl]-pyrrolidine-2-carboxylic acid (2-phenyl-2H-pyrazol-3-yl)-amide; inhibitors of IAP, for treating malignancies | BIRC5, BIRC2, XIAP | POLB 4146/4885NR3C2 4728/4885MAPK14 3461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.